Genomate Health

Genomate Health Genomate Health is a digital health company that develops computational solutions for personalized medicine.

By 2030, the world will see more than 24 million new cancer cases.That number is rising each year, not just because of a...
12/09/2025

By 2030, the world will see more than 24 million new cancer cases.

That number is rising each year, not just because of aging populations, but because we’re getting better at detection. Oncologists will face more complexity. More data. More patients needing fast, confident treatment decisions. And with that progress comes a new kind of pressure: how do we match each case to the right treatment, when time, evidence, and access are limited?

At Genomate Health, we’re focused on helping meet that challenge, by turning complex molecular data into clear, prioritized treatment options. Our computational reasoning platform supports clinical teams in making decisions that are evidence-based, scalable, and aligned with each patient’s biology.

As cancer care evolves, so must the tools we use to deliver it.

Explore the IARC Global Cancer Observatory projections: https://gco.iarc.fr/tomorrow/en/dataviz/isotype?years=2030&single_unit=500000

Grief is part of cancer care.Sometimes it arrives with loss.Sometimes with fear.Sometimes in the quiet moments after har...
12/03/2025

Grief is part of cancer care.
Sometimes it arrives with loss.
Sometimes with fear.
Sometimes in the quiet moments after hard decisions.

During Grief Awareness Week, we acknowledge something that often goes unsaid: treating cancer is not only about clinical outcomes. It’s about the patients, families and care teams carrying the emotional weight that comes with uncertainty, change, and loss.

At Genomate Health, we focus on clarity in complex moments. But we also recognize that no amount of data removes the human experience of grief.

To those living with it, moving through it, or holding space for others: our thoughts are with you.

A new study published in ESMO Open (2025) highlights why personalized cancer treatment matters. Patients whose therapies...
11/24/2025

A new study published in ESMO Open (2025) highlights why personalized cancer treatment matters. Patients whose therapies were matched to their tumor’s molecular profile lived nearly three times longer than those who didn’t receive matched treatment.

Even when the scientific evidence wasn’t yet considered the strongest, personalized treatment based on genetic markers made a clear difference.

At Genomate Health, we help make this kind of care more accessible. Our platform analyzes the full molecular profile of a tumor and helps clinicians prioritize treatment options that align with the biology of the disease, not just the diagnosis. Even in complex cases.

Read the study: https://www.esmoopen.com/article/S2059-7029%2825%2901640-0/fulltext

Pancreatic cancer doesn’t give us much time.Symptoms are often subtle. Diagnosis is often late. And treatment decisions ...
11/21/2025

Pancreatic cancer doesn’t give us much time.
Symptoms are often subtle. Diagnosis is often late. And treatment decisions can become urgent (and complex) very quickly.

At Genomate Health, we focus on helping clinicians make sense of that complexity. When treatment paths aren’t clear, our goal is to help uncover the next best step, based on the full molecular profile of the tumor, not just the diagnosis.

But before precision, there’s prevention.
If you notice ongoing fatigue, unexplained weight loss, digestive changes, or persistent pain, don’t dismiss it. Talk to your doctor.

We’re proud to share that Genomate Health has been recognized as one of GenomeWeb’s Best Places to Work in 2025. This re...
11/19/2025

We’re proud to share that Genomate Health has been recognized as one of GenomeWeb’s Best Places to Work in 2025.

This recognition highlights organizations across life science research, diagnostics, and precision medicine that foster flexible, inclusive, and supportive workplaces. For us, it reflects a culture built on curiosity, collaboration, and a deep commitment to transforming cancer care through computational reasoning.

At Genomate Health, keeping the patient at the center of everything we do drives our purpose and guides our work. Our team’s intellect, curiosity, and willingness to challenge ideas with respect are what make our organization a great place to grow and innovate.

Thank you to every member of our team, this honor is yours 💚

See the full list of winners: https://www.genomeweb.com/gw-best-places-to-work
Read our full press release: https://www.genomate.health/news-article/genomate-health-recognized-in-genomeweb-best-places-to-work-2025

11/19/2025

The early signs of gastric cancer are easy to miss; and even easier to ignore.
Indigestion. Bloating. Fatigue. Feeling full after just a few bites.

But these small symptoms can point to something more. And the earlier they’re caught, the more options patients have.

At Genomate Health, we focus on complex cancer decisions. But we also know that the best care starts with recognizing when something isn’t right and acting on it.

If symptoms persist, don’t wait. Talk to your doctor.
Because prevention starts with paying attention.

Most therapies are designed for the first battle.The real challenge is what to do when cancer adapts.Approvals like this...
11/17/2025

Most therapies are designed for the first battle.
The real challenge is what to do when cancer adapts.

Approvals like this reinforce a consistent need in lung cancer care: understanding the tumor’s evolving molecular profile. As new post-resistance therapies enter the clinic, having a clear view of each patient’s biomarkers helps determine when these treatments may be appropriate.

That’s the space where Genomate works: supporting clinicians with comprehensive molecular interpretation so decisions align with the biology.

Learn more: fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer

Every day in oncology, biomarkers change the course of care.They help identify what’s driving a tumor.They guide targete...
11/14/2025

Every day in oncology, biomarkers change the course of care.

They help identify what’s driving a tumor.
They guide targeted therapies.
They shape clinical trial decisions.
And sometimes, they offer a path forward when no clear option is left.

At Genomate Health, we focus on making that complexity usable.
Our computational reasoning platform analyzes the full molecular profile, helping oncologists move from uncertainty to clarity, especially when the next step isn’t obvious.

Because the value of a biomarker isn’t just in knowing it’s there.
It’s in knowing what to do next.

When molecular data is complex and the treatment path isn’t clear, the right decision often comes down to how well we un...
11/12/2025

When molecular data is complex and the treatment path isn’t clear, the right decision often comes down to how well we understand the biology behind the tumor.

At AACR-KCA 2025 in Busan, Istvan Petak MD, PhD, Founder and CSO of Genomate Health, will present new research on how knowledge-graph-based computational reasoning can help make those decisions more consistent, more evidence-based, and more actionable.

The abstract outlines how Genomate’s reasoning engine interprets the full molecular profile—not just single mutations—to prioritize therapies that align with the underlying biology of the cancer.

It’s an approach designed to support oncologists where they work, with the insights they need when decisions matter most. Learn more: https://www.genomate.health/event/genomate-at-aacr-kca-2025

How can we select the right targeted therapy, or clinical trial, for the right patient, at the right time?On November 12...
11/11/2025

How can we select the right targeted therapy, or clinical trial, for the right patient, at the right time?

On November 12, Dr. Istvan Petak, Founder and Chief Scientific Officer at Genomate Health, will explore this question as keynote speaker at the Clinical Diagnostics & Research 2025 virtual event, hosted by Labroots, Inc.

His session, titled "Selecting Targeted Cancer Therapies and Clinical Trials with Computational Reasoning," focuses on a challenge many oncologists face: making informed treatment decisions when the molecular profile doesn’t follow the textbook path. Dr. Petak will show how computational reasoning can help bring structure to molecular complexity—so clinicians can act with confidence, not uncertainty.

If you're working to make precision oncology more practical, scalable, and consistent across care settings, this is a talk you won’t want to miss.

Register to attend: https://www.labroots.com/virtual-event/clinical-diagnostics-research-2025

Neuroendocrine tumors (NETs) may share a name, but not a molecular signature. Behind each case lies a unique biology tha...
11/10/2025

Neuroendocrine tumors (NETs) may share a name, but not a molecular signature.

Behind each case lies a unique biology that can determine whether a patient benefits from targeted therapy, immunotherapy, or neither. That’s why precision matters.

NETs challenge traditional oncology approaches:
· Their growth is unpredictable.
· Their molecular drivers are diverse.
· Standard biomarkers don’t always tell the full story.

At Genomate Health, we help clinicians move beyond one-size-fits-all treatment by analyzing the full molecular context of each tumor. Our computational reasoning engine identifies actionable alterations, compensatory pathways, and therapy options that fit the biology of that individual NET, not just the label.

Because when cancer defies categories, only deeper understanding can guide the right care.

Learn more about how we make precision care scalable: https://www.genomate.health/

Honored to see our founder and Chief Scientific Officer, Dr. Peták István, included in ’s “AI25 – 25 Hungarians Behind t...
11/09/2025

Honored to see our founder and Chief Scientific Officer, Dr. Peták István, included in ’s “AI25 – 25 Hungarians Behind the Artificial Intelligence Revolution.”

This recognition is a wonderful acknowledgment of Istvan’s lifelong dedication to cancer research and his vision for making precision oncology accessible to every patient. His work continues to inspire all of us at Genomate Health to combine science and technology in service of better care and real human impact.

We’re grateful to see his efforts highlighted among so many brilliant minds shaping the future of AI: https://forbes.hu/extra/ai25/17-petak-istvan

Address

Cambridge, MA

Website

Alerts

Be the first to know and let us send you an email when Genomate Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Genomate Health:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category